Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Frost & Sullivan | PRODUCT CODE: 1691688

Cover Image

PUBLISHER: Frost & Sullivan | PRODUCT CODE: 1691688

Top 6 Growth Opportunities in Pharma-Biotech, 2025

PUBLISHED:
PAGES: 12 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Web Access (Regional License)
USD 2450

Add to Cart

Unlocking Growth in Precision Therapeutics, Digital Innovation, Manufacturing, and Emerging Markets

The pharmaceutical and biotechnology industries are entering a transformative era in 2025, shaped by a convergence of scientific innovation, regulatory evolution, and market pressures. One of the key imperatives is the continued advancement of therapeutics and drug approvals, as breakthrough treatments, particularly in personalized medicine, promise to revolutionize patient care. Oncology will remain the most valuable therapy area, while the immunomodulator segment will grow through existing blockbuster sales, and obesity and CNS will create fresh waves of growth rates. However, as new therapies emerge, drug pricing pressures are intensifying, with governments and insurers pushing for more cost-effective solutions, demanding greater value from pharmaceutical companies.

In response, manufacturers are optimizing production processes, increasing focus on efficient outsourcing, and embracing new manufacturing technologies to meet growing global demand while maintaining cost efficiency. At the same time, digital technologies and artificial intelligence (AI) are poised to accelerate R&D, streamlining drug discovery, optimizing clinical trials, and personalizing treatment pathways. These technological advancements are particularly pivotal in overcoming the complex challenges in pharmaceutical development.

Furthermore, emerging markets are becoming a central focus for growth. As populations in regions such as Asia, the Middle East, and Latin America continue to expand, pharmaceutical companies are seizing opportunities to tap into these dynamic markets, navigating unique regulatory and economic landscapes to deliver innovative solutions to underserved patient populations. These strategic imperatives' convergence is reshaping the future of the pharmaceutical and biotechnology industries in 2025.

Product Code: PFR2-52

Table of Contents

Top Growth Opportunities for 2025

  • Strategic Imperatives
  • Top 6 Growth Opportunities
  • Growth Opportunity 1: Radioligand Therapeutics is Fueling Precision Oncology
  • Growth Opportunity 2: Antibody Therapies are Revolutionizing Immunology and Inflammation
  • Growth Opportunity 3: The Pharmaceutical Market is Accessing IT Solutions to Ensure Higher Price Transparency
  • Growth Opportunity 4: Medical Co-pilots are Empowering Clinical Trial Peripheral Services
  • Growth Opportunity 5: APAC CDMOs are Scaling up Amid the Shifting Manufacturing Landscape
  • Growth Opportunity 6: Neuroprotective Therapy is Advancing Through Strategic Partnerships
  • Legal Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!